Published in J Urol on October 22, 2012
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep (2015) 1.30
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res (2015) 1.10
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res (2016) 0.79
On the origins of the androgen receptor low molecular weight species. Horm Cancer (2013) 0.78
Gαs protein expression is an independent predictor of recurrence in prostate cancer. J Immunol Res (2014) 0.75
Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel) (2017) 0.75
Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. J Steroid Biochem Mol Biol (2016) 0.75
Editorial comment. J Urol (2012) 0.75
Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin Cancer Res (2017) 0.75
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol (2004) 5.41
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol (2011) 2.04
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate (2006) 1.76
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Ancestral components of admixed genomes in a Mexican cohort. PLoS Genet (2011) 1.67
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol (2005) 1.63
Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer (2004) 1.61
Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res (2002) 1.43
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol (2006) 1.38
Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol (2003) 1.37
Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate (2009) 1.37
Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology (2003) 1.35
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell (2003) 1.30
Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A (2007) 1.30
Genetic architecture of skin and eye color in an African-European admixed population. PLoS Genet (2013) 1.28
Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res (2006) 1.28
Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol (2004) 1.28
Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology (2006) 1.27
Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res (2005) 1.27
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem (2003) 1.25
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene (2004) 1.20
Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis (2006) 1.17
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate (2004) 1.17
Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol (2010) 1.16
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer (2003) 1.15
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol (2003) 1.08
Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol (2005) 1.05
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res (2014) 1.05
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res (2012) 1.04
CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res (2004) 1.03
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol (2007) 1.03
Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol (2007) 1.02
The role of vitamin D in prostate cancer. Recent Results Cancer Res (2003) 1.02
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm (2010) 1.01
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med (2005) 0.97
Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res (2008) 0.96
Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res (2007) 0.94
Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate (2003) 0.94
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res (2002) 0.93
Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol (2002) 0.93
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology (2002) 0.92
The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol (2008) 0.92
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol (2003) 0.91
Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr (2007) 0.91
Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med (2009) 0.90
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett (2011) 0.90
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics (2009) 0.90
Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol (2003) 0.89
Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer (2009) 0.89
Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res (2006) 0.89
Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol (2010) 0.88
Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett (2005) 0.86
Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res (2012) 0.86
The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin. PLoS One (2011) 0.86
Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol (2002) 0.86
Induced pluripotency of human prostatic epithelial cells. PLoS One (2013) 0.86
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer (2013) 0.85
Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate (2013) 0.84
Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. J Clin Endocrinol Metab (2013) 0.84
Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate (2002) 0.84
Genetic profiling of Gleason grade 4/5 prostate cancer: which is the best prostatic control tissue? J Urol (2003) 0.83
The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2009) 0.82
Imaging the glycosylation state of cell surface glycoproteins by two-photon fluorescence lifetime imaging microscopy. Angew Chem Int Ed Engl (2013) 0.82
Stiffness mapping prostate biopsy samples using a tactile sensor. Conf Proc IEEE Eng Med Biol Soc (2011) 0.82
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med (2013) 0.81
Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater (2014) 0.81
Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.81
Molecular targets of doxazosin in human prostatic stromal cells. Prostate (2005) 0.81
Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer. Int J Radiat Oncol Biol Phys (2013) 0.81
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res (2012) 0.80
Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells. J Steroid Biochem Mol Biol (2004) 0.79
Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol (2004) 0.79
Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev (2007) 0.79
Biologic differences between peripheral and transition zone prostate cancer. Prostate (2014) 0.78
Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia. Prostate (2011) 0.78
Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett (2010) 0.77
Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate (2002) 0.77
Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. Nutr Rev (2007) 0.77
Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis (2014) 0.76
Using noun phrases for navigating biomedical literature on Pubmed: how many updates are we losing track of? PLoS One (2011) 0.75